| Autor: |
Li DH; The First School of Clinical Medicine,The First Hospital of Lanzhou University, Lanzhou 730000, Gansu Province, China., Yang JC; The First School of Clinical Medicine,The First Hospital of Lanzhou University, Lanzhou 730000, Gansu Province, China., Zhao L; Clinical Molecular Cytogenetics and Immunology Laboratory, The First Hospital of Lanzhou University, Lanzhou 730000, Gansu Province, China. E-mail: zhaoli@lzu.edu.cn. |
| Jazyk: |
čínština |
| Zdroj: |
Zhongguo shi yan xue ye xue za zhi [Zhongguo Shi Yan Xue Ye Xue Za Zhi] 2024 Feb; Vol. 32 (1), pp. 282-286. |
| DOI: |
10.19746/j.cnki.issn.1009-2137.2024.01.045 |
| Abstrakt: |
Acute myeloid leukemia(AML) is a malignant tumor of the blood system that is highly heterogeneous in terms of pathogenesis, genetic background and prognostic outcome, with an extremely high fatality rate and recurrence rate. Therefore, exploring new treatment methods and diagnostic strategies is one of the ways to improve the survival rate of patients with acute myeloid leukemia. Circular RNA (circRNA) is a special kind of noncoding RNA, which plays an important role in gene transcription, translation and epigenetic modification, and participates in the disease progression and prognosis of multiple solid tumors. At present, it has found that the abnormal expression of circRNA is closely related to the occurrence, development, drug resistance and prognosis of acute myeloid leukemia.Clinically, it can be used as a new biomarker and potential therapeutic target for AML. This article briefly reviews the research progress of circRNA in acute myeloid leukemia, aiming to provide new strategies for optimizing the diagnosis, treatment and prognosis of leukemia. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
